Creating a skin patch to relieve nausea and vomiting during pregnancy
Official title: Development of an Ondansetron Transdermal Patch for Pregnancy-Induced Nausea and Vomiting
Funded at Integurx Therapeutics LLC · NIH-11008000 · Data updated 2026-11-12
This study is working on a new skin patch that delivers ondansetron to help pregnant people who are dealing with nausea and vomiting, making it easier for them to get relief without having to take pills.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Integurx Therapeutics LLC NIH-funded |
| Lab location | 1 site (Califon, United States) |
| Project start | September 1, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $333,284 |
| NIH project number | 1R43HD116663-01 |
| Project ID | NIH-11008000 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are pregnant individuals experiencing nausea and vomiting, particularly during the first and early second trimesters.
✕Less likely to help
Patients who are not pregnant or those who do not experience nausea and vomiting during pregnancy may not benefit from this research.
What this research studies
This research focuses on developing a transdermal patch that delivers ondansetron, a medication used to treat pregnancy-induced nausea and vomiting (PINV). The patch is designed to be applied once or twice a week, providing a continuous release of the medication without the need for oral ingestion, which can be difficult for those experiencing severe nausea. The project aims to enhance the absorption of ondansetron through the skin significantly, making it a more effective treatment option for pregnant individuals suffering from PINV. The research has already received guidance from the FDA on the regulatory approval process, indicating a clear path forward for the product's development.
Why it matters
Potential benefit: If successful, this research could provide a more convenient and effective treatment option for pregnant individuals suffering from debilitating nausea and vomiting.
How similar studies have gone: While there are existing treatments for PINV, the transdermal delivery method being explored in this research is novel and has not been widely tested in this context.
Where this research is happening
-
Integurx Therapeutics LLC
Califon, United States Active
Researchers
- Principal investigator: Shangold, Gary — Integurx Therapeutics LLC
- Study coordinator: Shangold, Gary
Related research
Other NIH-funded projects on the same topics.
-
How air pollution during pregnancy affects fetal growth over time
This study looks at how air pollution affects the growth of babies in the womb during pregnancy, using ultrasound images to track changes over time, and it aims to help expectant parents understand when their babies might be most at risk from pollution.
-
Postoperative Pain Guidelines for Pregnancy: Safer, Patient-Centered Opioid Use
We’re creating patient-friendly guidelines to help doctors manage pain after delivery and surgery in pregnant people, aiming to reduce opioid overuse and improve safety.
-
HPV and pregnancy risk: a big study following 1,280 pregnancies
A large pregnancy study at UTMB looks at whether human papillomavirus (HPV) during pregnancy is linked to problems like preterm birth.
-
Understanding how where you live and personal factors during pregnancy affect a child’s risk for obesity and metabolic problems
This project looks at how neighborhood conditions and individual factors during pregnancy may influence a child’s risk of obesity and metabolic health as they grow.
-
Blocking cancer-causing cMYC tricks after pregnancy changes in the breast
Researchers are testing how pregnancy and aging reshape the breast before cancer risk, using patient-reinformed models to see if it changes how dangerous cMYC signals behave.
-
SSRI use during pregnancy: effects on placental blood flow and inflammation
This grant studies how antidepressants (SSRIs) used during pregnancy might affect the placenta and inflammation, and whether a 5-HT2 receptor blocker could mitigate any negative effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.